Ribas, A. & Wolchok, J.D. Cancer immunotherapy using checkpoint inhibition. Science 359, 1350–1355 (2018).
Rohaan, MW et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med. 387, 2113–2125 (2022).
Rosenberg, SA & Restifo, NP Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).
Klebanoff, CA, Chandran, SS, Baker, BM, Quezada, SA & Ribas, A. T-cell receptor therapy: immunological targeting of the intracellular cancer proteome. Nat. Rev. Drug Discov. 22, 996–1017 (2023).
Simoni, Y. et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumor infiltrates. Nature 557, 575–579 (2018).
Scheper, W. et al. Low and variable tumor reactivity of intratumoral TCR repertoires in human cancers. Nat. Med. 25, 89–94 (2019).
Schumacher, T. N., Scheper, W. & Kvistborg, P. Cancer neoantigens. Annu. Immunol Rev. 37, 173–200 (2019).
Schumacher, TN & Schreiber, RD “Neoantigens in cancer immunotherapy.” Science 348, 69–74 (2015).
Gros, A. et al. Prospective identification of neoantigen-specific lymphocytes in peripheral blood of melanoma patients. Nat. Med. 22, 433–438 (2016).
Gubin, MM et al. Checkpoint blockade cancer immunotherapy targets tumor-specific mutant antigens. Nature 515, 577–581 (2014).
Rizvi, NA et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 inhibition in non-small cell lung cancer. Science 348, 124–128 (2015).
Alspach, E. et al. MHC-II neoantigens shape tumor immunity and responses to immunotherapy. Nature 574, 696–701 (2019).
Oh, DY et al. Intratumoral CD4+ T cells mediate antitumor cytotoxicity in human bladder cancer. Cell 181, 1612–1625 (2020).
Tran, E. et al. Mutation-specific CD4+ T cell-based cancer immunotherapy in patients with epithelial cancer. Science 344, 641–645 (2014).
Borst, J., Ahrends, T., Babala, N., Melief, CJM & Kastenmuller, W. CD4+ T cell help in cancer immunology and immunotherapy. Nat. Rev. Immunol. 18, 635–647 (2018).
Hu, Z. et al. A cloning and expression system to probe T cell receptor specificity and evaluate functional affinity for neoantigens. Blood 132, 1911–1921 (2018).
Guo, XZ et al. Rapid cloning, expression, and functional characterization of paired αβ and γδ T cell receptor chains by single-cell analysis. Mol. Ther. Methods Clin. Dev. 3, 15054 (2016).
Zong, S. et al. Extremely rapid cloning, expression, and specificity identification of T cell receptors for T cell engineering. PLoS ONE 15, e0228112 (2020).
Genolet, R. et al. TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs. Cell Rep. Methods 3, 100459 (2023).
Fahad, AS et al. Immortalization and functional screening of native-paired human T cell receptor repertoires. Protein Eng. Des. Sel. 35, gzab034 (2022).
Spindler, MJ et al. Massively parallel exploration and mining of the native-paired human TCRαβ repertoire. Nat. Biotechnol. 38, 609–619 (2020).
Muller, TR et al. A T cell reporter platform for high-throughput and reliable interrogation of TCR function and biology. Clin. Transl. Immunol. 9, e1216 (2020).
Fahad, AS et al. Screening of native-paired human T cell receptor repertoires based on cell activation. Sci. Rep. 13, 8011 (2023).
Vazquez-Lombardi, R. et al. High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity. Immunity 55, 1953–1966 (2022).
Cattaneo, CM et al. Identification of patient-specific CD4+ and CD8+ T cell neoantigens by HLA-unbiased genetic screening. Nat. Biotechnol. 41, 783–787 (2023).
Lowery, FJ et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancer. Science 375, 877–884 (2022).
Gros, A. et al. PD-1 identifies patient-specific CD8+ tumor-reactive repertoires infiltrating human tumors. J. Clin. Invest. 124, 2246–2259 (2014).
Arnaud, M. et al. Sensitive identification of neoantigens and cognate TCRs in human solid tumors. Nat. Biotechnol. 40, 656–660 (2022).
Foy, SP et al. Nonviral precision T cell receptor replacement for personalized cell therapy. Nature 615, 687–696 (2022).
Hilf, N. et al. An aggressive personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240–245 (2019).
Ott, PA et al. Immunogenic personalized neoantigen vaccines for melanoma patients. Nature 547, 217–221 (2017).
Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptome data across different conditions, techniques, and species. Nat. Biotechnol. 36, 411–420 (2018).
Lefranc, MP et al. “25 years of IMGT®, the International Immunogenetic Information System®.” Nucleic Acids Res. 43, D413–D422 (2015).
Chen, X. & Porter, E. Compositions and methods for T cell receptor gene assembly. Patent WO2020206238A2 (2020).
Klein, JC et al. Multiplexed pairwise assembly of array-derived DNA oligonucleotides. Nucleic Acids Res. 44, e43 (2016).
Chapuis, AG et al. WT1-targeted T cell receptor gene therapy prevents relapse of acute myeloid leukemia after transplantation. Nat. Med. 25, 1064–1072 (2019).
Schmitt, TM, Greenberg, PD & Nguyen, HN WT-1-specific T cell immunotherapy. US Patent US20160083449A1 (2015).
Borbulevych, OY, Santhanagopolan, SM, Hossain, M. & Baker, BM TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms. J. Immunol. 187, 2453–2463 (2011).
Johnson, LA et al. Gene transfer of tumor-reactive TCRs confers both high affinity and tumor reactivity to non-reactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J. Immunol. 177, 6548–6559 (2006).
Kwakkenbos, MJ et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat. Med. 16, 123–128 (2010).
Moravec, Z. et al. Functional discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening: validation in CD8 T cells. NCBI sequence read archive https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1068078 (2024).
Moravec, Z. et al. Functional discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening: validation in CD4 T cell and OVC190 TCR screens. NCBI sequence read archive https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1068299 (2024).
Moravec, Z. et al. Functional discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening: the NKIRTIL063 titration screen. NCBI sequence read archive https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1068301 (2024).
Moravec, Z. et al. Functional discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening: the NKIRTIL063 neoantigen screen. NCBI sequence read archive https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1068303 (2024).